Scoop: Blade Therapeutics CEO, CFO appear to depart amid 'transition' after nixed SPAC
The two top executives at Blade Therapeutics appear to no longer be with the biotech after the startup failed to merge with its SPAC partner earlier this year.
The biotech’s CEO and CFO no longer list the San Francisco-based drug developer as their employer on their LinkedIn pages, and other employee profiles list themselves as “open to work.” When reached via LinkedIn on Thursday, former CEO Wendye Robbins said the company is “in the middle of a transition.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.